Pfizer Zyrtec-D Labeled "Rx-only" Pending Antihistamine OTC Switch Decision
Executive Summary
Pfizer's antihistamine/decongestant combination product Zyrtec-D has been approved as "Rx-only" pending decision on over-the-counter switch status of the antihistamine class.
You may also be interested in...
Pfizer/Pharmacia Bextra Will Be Premium Priced, In Pharmacies Feb. 15
Pharmacia/Pfizer's COX-2 inhibitor Bextra will be launched at a 10% price premium over Celebrex and Vioxx
Pfizer/Pharmacia Bextra Will Be Premium Priced, In Pharmacies Feb. 15
Pharmacia/Pfizer's COX-2 inhibitor Bextra will be launched at a 10% price premium over Celebrex and Vioxx
FDA Has "Legal Recourse" To Force Rx-To-OTC Switch Of Antihistamines
FDA has the authority to switch prescription products to over-the-counter status and could resort to legal remedies if the switch is opposed by the drugs' manufacturers, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.